23andMe's former CEO agrees to buy the company for $305 million

Anne Wojcicki is set to regain control of bankrupt genetics testing company 23andMe after agreeing to acquire its assets for $305 million through TTAM Research Institute, a public-benefit corporation solely listing Wojcicki. This follows Regeneron's withdrawal from the bidding process, citing concerns over 23andMe's remaining value, despite an initial $265 million bid. Wojcicki's move, funded entirely from her personal fortune, aims to revive 23andMe despite its significant $666 million loss in the last fiscal year and declining revenue since a 2023 data breach, though questions remain about her strategy for achieving viability.

Analysis

Anne Wojcicki is set to regain control of the bankrupt genetics testing company 23andMe through a $305 million bid made via TTAM Research Institute, a newly formed public-benefit corporation solely listing Wojcicki and funded entirely by her personal fortune. This development follows a competitive bidding process where Regeneron Pharma, initially winning with a $265 million offer, subsequently withdrew, with CEO Leonard Schleifer stating "the juice isn't worth the squeeze," indicating a negative assessment of 23andMe's remaining value. The company faces substantial headwinds, having incurred a $666 million loss in its last fiscal year prior to bankruptcy, coupled with declining revenue since a 2023 data breach. This data breach and the proposed sale have also attracted significant legal and regulatory scrutiny, including a congressional inquiry and lawsuits from 27 state attorneys general concerned about consumer consent. Despite Wojcicki's commitment, underscored by a significant personal financial investment and her original role in building customer trust, considerable uncertainty remains regarding her strategy to achieve viability for 23andMe, particularly as longtime board members had previously lost faith in her strategic direction. The court is scheduled to review Wojcicki's bid, but even if approved, the path to a sustainable business model appears challenging given the company's recent performance and the founder's decision to double down on a previously questioned approach.

Key Decisions for Investors

• The re-acquisition of 23andMe by its founder underscores the extreme financial distress and high-risk nature of turnaround efforts in the direct-to-consumer genetics testing sector, particularly following significant data breaches and substantial operating losses.
• Regeneron's (REGN) withdrawal from the acquisition, citing insufficient value, signals caution from established pharmaceutical companies regarding distressed assets in this space, potentially influencing valuation benchmarks for similar entities.
• Investors should monitor the legal approval of Wojcicki's bid and any subsequent details of her turnaround strategy, as the success or failure of 23andMe under a public-benefit structure could offer insights into managing data-intensive businesses facing trust and viability crises.
• This situation highlights the critical importance of robust data security, consumer trust, and sustainable revenue models for companies in the personal genetics and broader data-centric industries, serving as a cautionary tale for investments in businesses with comparable risk profiles.